Scynexis Company Profile (NASDAQ:SCYX)

Analyst Ratings

Consensus Ratings for Scynexis (NASDAQ:SCYX) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.60 (622.77% upside)

Analysts' Ratings History for Scynexis (NASDAQ:SCYX)
Show:
DateFirmActionRatingPrice TargetActions
6/9/2016Needham & Company LLCReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016WBB SecuritiesInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Royal Bank Of CanadaLower Price TargetOutperform$18.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Scynexis (NASDAQ:SCYX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/17/2016        
5/9/2016Q116($0.63)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.62)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.43)($0.75)$4.20 million$2.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015($0.71)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.53)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Scynexis (NASDAQ:SCYX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Scynexis (NASDAQ:SCYX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Scynexis (NASDAQ:SCYX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2016Gonzalez David AnguloInsiderBuy36,950$2.22$82,029.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Eric FrancoisCFOBuy15,000$2.39$35,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Guy MacdonaldDirectorBuy40,000$2.39$95,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Marco TagliettiCEOBuy100,000$2.39$239,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Ann HanhamDirectorBuy4,225$3.64$15,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Marco TagliettiCEOBuy5,754$3.26$18,758.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Marco TagliettiCEOBuy5,500$3.37$18,535.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Marco TagliettiCEOBuy7,500$3.14$23,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Marco TagliettiCEOBuy6,000$3.07$18,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Marco TagliettiCEOBuy22,733$6.79$154,357.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Marco TagliettiCEOBuy25,000$7.82$195,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marco TagliettiCEOBuy2,267$7.08$16,050.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Marco TagliettiCEOBuy50,000$7.07$353,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Jean-Yves NothiasDirectorBuy50,000$10.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Ventech Capital IiMajor ShareholderBuy28,000$10.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Scynexis (NASDAQ:SCYX)
DateHeadline
07/21/16 06:38 PMInsiders Increasing Positions in: SCYNEXIS, Inc. (NASDAQ:SCYX) - Press Telegraph
07/19/16 07:26 AMScynexis Incorporated (NASDAQ:SCYX) Shorted Shares Increased By 87.29% - Press Telegraph
07/19/16 07:26 AMInvestor Watch: Volatility Recap on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/19/16 07:26 AMNew Broker Ratings For SCYNEXIS, Inc. (SCYX) - FTSE News
07/17/16 10:23 AMShares Moving Down on the Week: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/17/16 10:23 AMSCYNEXIS, Inc. (SCYX) Broker Price Targets For The Coming Week - Fiscal Standard
07/15/16 11:34 AMEye on Stock Volatility for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/15/16 11:34 AMIncreased Volatility Noted on Shares of: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/15/16 11:34 AMBroker Outlook For SCYNEXIS, Inc. (SCYX) - Fiscal Standard
07/13/16 06:42 PMScynexis (SCYX) Sells Cyclophilin Inhibitor Assets to Cypralis - StreetInsider.com
07/13/16 06:42 PMShare Volatility Watch for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/13/16 07:48 AMSCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited - [at noodls] - JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis ...
07/08/16 09:12 AMScynexis Incorporated (NASDAQ:SCYX) Short Interest Increased By 87.29% - Engelwood Daily
07/08/16 09:12 AMFollowing Unusual Volume for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
07/06/16 08:21 AMSCYNEXIS, Inc. to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald's 2 Annual Healthcare Conference ...
07/06/16 08:05 AMSCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - JERSEY CITY, N.J., July 06, 2016-- Drug development company SCYNEXIS, Inc. today announced that the Company will present at Cantor Fitzgerald’ s 2 nd Annual Healthcare Conference at Le Parker Meridien ...
07/05/16 10:43 AMSCYNEXIS Inc (NASDAQ:SCYX)'s Company Shares Decreased 45.11% After Low Volatility - Press Telegraph
07/05/16 10:43 AMAnalysts Rating updates about two Stocks: SCYNEXIS, Inc. (NASDAQ:SCYX) , Idera Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/03/16 05:36 PMCompany Stock Lower on the Week SCYNEXIS, Inc. (NASDAQ:SCYX) - Engelwood Daily
06/29/16 06:14 PMScynexis Inc (SCYX) CEO Marco Taglietti Bought $239000 of Stocks - GuruFocus.com
06/29/16 08:42 AMBuying Spree of Ambac Financial Group Inc. (AMBC)’s CEO Continues, Plus Noteworthy Insider Buying Activity at Two Other Companies -
06/28/16 06:13 PMScynexis Inc (SCYX) CEO Marco Taglietti Bought $239,000 of Stocks
06/25/16 10:00 AMShare Volatility Check for: SCYNEXIS, Inc. (NASDAQ:SCYX) - Press Telegraph
06/23/16 06:57 PMScynexis Inc (NASDAQ:SCYX) Sinks a Bit Following a Dilution-Inducing Move
06/23/16 08:57 AMScynexis Inc (NASDAQ:SCYX) Sinks a Bit Following a Dilution-Inducing Move - HotStocked
06/22/16 06:16 PMSCYNEXIS, Inc. (SCYX) Updated Price Targets - FTSE News
06/22/16 11:01 AMSCYNEXIS : Announces Launch of Public Offering of Common Stock and Warrants
06/22/16 11:01 AMScynexis (SCYX) Prices $22.5M Common Stock, Warrants Offering
06/21/16 05:49 PMToday's Stocks: SCYNEXIS, Inc. (NASDAQ:SCYX), ITI Inc (NASDAQ:ITCI), O'Reilly Automotive Inc. (NASDAQ:ORLY ... - KC Register
06/21/16 10:38 AMStocks Swings: SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Ocean Bio-Chem Inc. (NASDAQ ... - KC Register
06/21/16 10:38 AMAnalyst Views For The Week Ahead: SCYNEXIS, Inc. (SCYX) - Fiscal Standard
06/21/16 08:39 AMSCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants - [at noodls] - JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to ...
06/20/16 06:00 PMAfter-Hours Stock Movers 06/20: (IMPV) (NWY) (OPK) Higher; (SCYT) (WERN) (SWFT) Lower (more...)
06/20/16 03:09 PMSCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants - [at noodls] - JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase ...
06/20/16 07:00 AMSCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections - [GlobeNewswire] - SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat ...
06/15/16 06:12 PMSCYNEXIS, Inc. (NASDAQ:SCYX) Tumbled -9.03%: Bristol-Myers Squibb Company (NYSE:BMY), ONEOK Partners ... - KC Register
06/10/16 09:20 AMYesterday Trading Recap: Juno Therapeutics, Inc. (NASDAQ:JUNO) , SCYNEXIS, Inc. (NASDAQ:SCYX) - Street Updates
06/10/16 08:19 AMSCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016 - [at noodls] - JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the company's lead ...
06/09/16 06:48 PMAnalysts Offer Insights on Healthcare Companies: SCYNEXIS Inc (NASDAQ: SCYX), Opexa Therapeutics (NASDAQ ... - Analyst Ratings
06/08/16 06:50 PMScynexis (SCYX) Issues Positive Update on Oral SCY-078 Phase 2 vs. Current Standard of Care
06/08/16 03:18 PMSCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors - [at noodls] - Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J., June 08, ...
06/07/16 03:27 PMSCYNEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 12:24 PMSCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 09:03 AMSCYNEXIS Gets Orphan Drug Status For SCY-078 -
05/13/16 08:58 AMSCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections - [at noodls] - JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...
05/09/16 08:48 AMSCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update - [at noodls] - JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an update on ...
05/09/16 08:30 AMScynexis reports 1Q loss -
04/19/16 08:36 AMSCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency - [at noodls] - JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise (SME) status ...
04/15/16 08:33 AMSCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis - [at noodls] - JERSEY CITY, N.J., April 15, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company's lead clinical drug ...
04/11/16 03:58 PMSCYNEXIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -

Social

About Scynexis

Scynexis logoSCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SCYX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.02
  • 50 Day Moving Average: $2.28
  • 200 Day Moving Average: $3.76
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $28.09M
  • Beta: 0.25
  • Current Year EPS Consensus Estimate: $-2.44 EPS
  • Next Year EPS Consensus Estimate: $-2.51 EPS
Additional Links:
Scynexis (NASDAQ:SCYX) Chart for Sunday, July, 31, 2016